News

The January 2023 cardiology month in review features a trio of articles related to management of atrial fibrillation, the FDA approval of Abbott’s Navitor system, and a study spotlighting the prevalence of mental health conditions among cardiologists.

In this recent study, mental health conditions associated with alopecia areata were assessed by the study’s investigators.

A sugary drinks tax in England may have prevented over 5,000 cases of obesity a year in older girls, but had no significant association with obesity levels in year six boys or younger children.

The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi's long-term dedication to biosimilars.

The clinical trials that supported the FDA decision, SEQUOIA and ALPINE, evaluated the efficacy of zanubrutinib and findings paved the way to add the therapy as a treatment option.

A ED screening program identified a substantial number of patients with undiagnosed prediabetes and T2D or undermanaged disease, particularly racial and ethnic minorities.

The latest HCPLive interview segment with Karan Lal, DO, discussing his views on what can go wrong during cosmetic procedures.

The study population consists of patients who received 1-3 prior lines of therapy for relapsed and lenalidomide-refractory multiple myeloma.

The new polymerase chain reaction method was evaluated for specificity, sensitivity, and repeatability using 69 C difficile isolates and 74 fecal samples.

A new interview segment with Karan Lal, DO, in which he explores the benefits and drawbacks of dermatology offices versus medical spas.

MDR colonization was associated with MDR infection and colonization and infection was linked to higher numbers and duration of antibiotic use.

A study of more than 100 adults with type 1 diabetes suggests those with increased levels of self-stigma had worse glucose control than their counterparts with lower levels of self-stigma.

The company announced they will no longer pursue approval for the treatment despite positive data from recent phase 2 trials.

Abbott's Proclaim XR spinal cord stimulation system allows patients with painful diabetic peripheral neuropathy to improve quality of life using a system that is easily incorporated into their everyday lives.

The monoclonal antibody serves as the first and only therapy for treating hemolysis in adults with cold agglutinin disease, an extremely rare condition.

Real-world evidence indicates that patients with psoriasis can safely and effectively undergo (non-medical) switching to a biosimilar.

An analysis of the Jackson Heart Study reports economic food insecurity as a risk factor for incident CHD and incident HFrEF, independent of socioeconomic measures and traditional CV risk factors.

“Repurposing approved drugs developed for other conditions presents an attractive strategy to identify new treatment options and expand access to potentially lifesaving care,” investigators wrote.

Rurality was associated with an increased risk of HF among women and Black men, which persisted after adjustment for cardiovascular risk factors and socioeconomic status.

With up to 40 years of follow-up, a retrospective study of matched pairs is providing an overview of the long-term risks and benefits of bariatric surgery in people with overweight or obesity.

Patients with COVID-19 and CDI had a higher incidence of sepsis, shock, ICU admission, and acute kidney injuries.

The house dust mite allergen extract was approved by the FDA for treating adolescents with immunotherapy.

Individuals with level 3 care needs, participants with hypertension or stroke and residents who used canes were at a higher risk of developing norovirus-related diarrhea.

An analysis of 2 decades worth of data from the Clinical Practice Research Datalink suggests all-cause mortality rates in type 2 diabetes have decreased but sheds light on upward trends in mortality from multiple different forms of cancer, including pancreatic, liver, and lung cancer, particularly among older patients.

Recent findings indicated that patients with new-onset psoriasis may see positive results from switching to secukinumab treatment.

Announced on January 24, the US FDA's marketing clearance for the Tidepool Loop mobile app allows for use with compatible devices for automated insulin dosing to help manage type 1 diabetes in persons 6 years of age and older.

Participants in the Tromsø study with both obesity and moderately high/high waist circumference at baseline had increased odds of being frail compared with those in the normal range.

Shifts towards on-patient and higher-cost therapies have been observed in TNF-alpha inhibitor biosimilar availability. Therefore, the importance of investing in biosimilars is encouraged.